Article Data

  • Views 1404
  • Dowloads 196


Open Access Special Issue

The 100 most-cited articles in castration-resistant prostate cancer: a bibliometric analysis

  • Hui Fang1,2,†
  • Lugeng He3,†
  • Huadong He3
  • Xuliang Wang3
  • Yuyong Wang3
  • Hongwei Ge3
  • Yuehua Wan1,2,†,*,
  • Chao Chen3,†,*,

1Institute of Information Resource, Zhejiang University of Technology, 310014 Hangzhou, China

2Library, Zhejiang University of Technology, 310014 Hangzhou, China

3Department of Urology, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, 310006 Hangzhou, China

DOI: 10.31083/jomh.2021.053 Vol.18,Issue 1,January 2022 pp.1-8

Submitted: 23 February 2021 Accepted: 09 March 2021

Published: 31 January 2022

(This article belongs to the Special Issue Therapy and prognosis of metastatic prostate cancer)

*Corresponding Author(s): Yuehua Wan E-mail:
*Corresponding Author(s): Chao Chen E-mail:

† These authors contributed equally.


Purpose: To assess the present landscape and future research directions, a bibliometric analysis was performed to identify the characteristics of the 100 most-cited articles (T100 articles) on CRPC research.

Methods: A list of the T100 articles investigating CRPC was generated by searching the Web of Science (WoS) Core Collection database. Different characteristics of the T100 articles, including the countries/territories, journals, authors, and research areas, were analyzed.

Results: The number of citations of T100 articles published between 1992 and 2017 ranged from 282 to 3594, with an average of 654.9 citations. According to the topic of the article, ''Mechanisms related to tumor progression or metastasis'' ranked first with 41 T100 articles, while immunotherapy ranked fourth with 7 T100 articles. The T100 articles originated from 31 countries, with more than half originating from the USA (n = 89). Professor Scher HI published the most T100 articles as the first author (4) and as the corresponding author (5), while Pro De Bono JS from the Institute of Cancer Research published 3 articles as the first author and 8 articles as the corresponding author. The journal Cancer Research published 20 T100 articles with a total of 8946 citations. The number of T100 articles(r = 0.485, P = 0.01) and the total number of citations(r = 0.626, P < 0.001) were all positively correlated with the IF of the journal.

Conclusions: This analysis offers a historical perspective on the progress and attempts to reveal future trends in CRPC research using bibliometric analysis. This study's results suggest that immunotherapy and the study of androgen receptors as well as their signaling axes will possibly be hot topics and trends in CRPC research.


Castration-resistant prostate cancer (CRPC); Mechanism; Tumor progression; Metastasis; Immunotherapy; Bibliometric analysis

Cite and Share

Hui Fang,Lugeng He,Huadong He,Xuliang Wang,Yuyong Wang,Hongwei Ge,Yuehua Wan,Chao Chen. The 100 most-cited articles in castration-resistant prostate cancer: a bibliometric analysis. Journal of Men's Health. 2022. 18(1);1-8.


[1] Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U, et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. New England Journal of Medicine. 2018; 378: 2465–2474.

[2] Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. European Urology. 2017; 71: 630–642.

[3] Saad F, Shore N, Zhang T, Sharma S, Cho HK, Jacobs IA. Emerging therapeutic targets for patients with advanced prostate cancer. Cancer Treatment Reviews. 2019; 76: 1–9.

[4] Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR- SIOG guidelines on prostate cancer. Part II-2020 update: treatment of relapsing and metastatic prostate cancer. European Urology. 2021; 79: 263–282.

[5] Gillessen S, Attard G, Beer TM, Beltran H, Bossi A, Bristow R, et al. Management of patients with advanced prostate cancer: the report of the advanced prostate cancer consensus conference APCCC 2017. European Urology. 2018; 73: 178–211.

[6] Azer SA, Azer S. Top-cited articles in medical professionalism: a bibliometric analysis versus altmetric scores. BMJ Open. 2019; 9: e029433.

[7] Bao G, Fang H, Chen L, Wan Y, Xu F, Yang Q, et al. Soft robotics: academic insights and perspectives through bibliometric analysis. Soft Robotics. 2018; 5: 229–241.

[8] Chen Y, Jin Q, Fang H, Lei H, Hu J, Wu Y, et al. Analytic network process: academic insights and perspectives analysis. Journal of Cleaner Production. 2019; 235: 1276–1294.

[9] Bao G, Pan L, Fang H, Wu X, Yu H, Cai S, et al. Academic review and perspectives on robotic exoskeletons. IEEE Transactions on Neural Systems and Rehabilitation Engineering. 2019; 27: 2294–2304.

[10] Kim HJ, Yoon DY, Kim ES, Lee K, Bae JS, Lee J. The 100 most-cited articles in neuroimaging: a bibliometric analysis. NeuroImage. 2016; 139: 149–156.

[11] Eule C, Bhulani N, Paulk E, Rhodes R, Beg MS. Characteristics and impact of the most-cited palliative oncology studies from 1995 to 2016. BMC Cancer. 2018; 18: 1281.

[12] Berlinberg A, Bilal J, Riaz IB, Kurtzman DJB. The 100 top-cited publications in psoriatic arthritis: a bibliometric analysis. International Journal of Dermatology. 2019; 58: 1023–1034.

[13] He L, Fang H, Wang X, Wang Y, Ge H, Li C, et al. The 100 most-cited articles in urological surgery: a bibliometric analysis. International Journal of Surgery. 2020; 75: 74–79.

[14] Montinaro V, Giliberti M, Villani C, Montinaro A. Citation classics: ranking of the top 100 most cited articles in nephrology. Clinical Kidney Journal. 2020; 12: 6–18.

[15] He L, Fang H, Chen C, Wu Y, Wang Y, Ge H, et al. Metastatic castration-resistant prostate cancer: Academic insights and perspec-tives through bibliometric analysis. Medicine. 2020; 99: e19760.

[16] Takeshima Y, Suzuki M, Miyakawa J, Tsuru I, Yamada Y, Nakamura M, et al. Latent prostate cancer among Japanese males: a bibliometric study of autopsy reports from 1980–2016. Japanese Journal of Clinical Oncology. 2021; 51: 156–159.

[17] Sweileh WM. Global research trends of World Health Organization’s top eight emerging pathogens. Globalization and Health. 2017; 13: 9.

[18] Manzano-Agugliaro F, Alcayde A, Montoya FG, Zapata-Sierra A, Gil C. Scientific production of renewable energies worldwide: an overview. Renewable and Sustainable Energy Reviews. 2013; 18: 134–143.

[19] Konur O. Scientometric evaluation of the global research in spine: an update on the pioneering study by Wei et al. European Spine Journal. 2018; 27: 524–529.

[20] Aggarwal A, Lewison G, Rodin D, Zietman A, Sullivan R, Lievens Y. Radiation therapy research: a global analysis 2001-2015. International Journal of Radiation Oncology, Biology, Physics. 2019; 101: 767–778.

[21] Boudry C, Baudouin C, Mouriaux F. International publication trends in dry eye disease research: a bibliometric analysis. The Ocular Surface. 2018; 16: 173–179.

[22] Musa TH, Ahmad T, Li W, Kawuki J, Wana MN, Musa HH, et al. A bibliometric analysis of global scientific research on scrub typhus. BioMed Research International. 2020; 2020: 5737893.

[23] Arshad AI, Ahmad P, Karobari MI, Asif JA, Alam MK, Mahmood Z, et al. Antibiotics: a bibliometric analysis of top 100 classics. Antibiotics. 2020; 9: 219.

[24] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2019; 68: 394–424.

[25] Rodwin MA. Reforming pharmaceutical industry-physician financial relationships: lessons from the United States, France, and Japan. The Journal of Law, Medicine & Ethics. 2011; 39: 662–670.

[26] Lewison G, Purushotham A, Mason M, McVie G, Sullivan R. Understanding the impact of public policy on cancer research: a bibliometric approach. European Journal of Cancer. 2010; 46: 912–919.

[27] Wallace TA, Martin DN, Ambs S. Interactions among genes, tumor biology and the environment in cancer health disparities: examining the evidence on a national and global scale. Carcinogenesis. 2011; 32: 1107–1121.

[28] Scher HI, Fizazi K, Saad F, Taplin M, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. The New England Journal of Medicine. 2012; 367: 1187–1197.

[29] Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, et al. Placebo-controlled phase III trial of immunologic therapy with Sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. Journal of Clinical Oncology. 2006; 24: 3089–3094.

[30] Higano CS, Small EJ, Schellhammer P, Yasothan U, Gubernick S, Kirkpatrick P, et al. Sipuleucel-T. Nature Reviews Drug Discovery. 2010; 9: 513–514.

[31] Scher HI, Graf RP, Hulling M, Carbone E, Dittamore R. Use of nuclear-localized androgen receptor splice variant 7 protein in CTCs after 1st androgen receptor signaling inhibitor (ARSi) as a predictive biomarker for overall survival on a second ARSi or taxane chemotherapy in metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology. 2018; 29: viii292–viii293.

[32] de Bono JS, De Giorgi U, Rodrigues DN, Massard C, Bracarda S, Font A, et al. Randomized phase II study evaluating Akt blockade with ipatasertib, in combination with abiraterone, in patients with metastatic prostate cancer with and without PTEN loss. Clinical Cancer Research. 2019; 25: 928–936.

[33] de Bono JS, Concin N, Hong DS, Thistlethwaite FC, Machiels J, Arkenau H, et al. Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial. The Lancet Oncology. 2019; 20: 383–393.

[34] Small EJ, Lee JY, Lopez-Gitlitz A, Saad F, Rooney B, Hadaschik BA, et al. Prostate-specific antigen (Psa) outcomes in patients (Pts) with nonmetastatic castration-resistant prostate cancer (Nmcrpc) treated with apalutamide (Apa): results from phase 3 spartan study. Journal of Urology. 2018; 199: E232–E232.

[35] Luo J, Attard G, Balk SP, Bevan C, Burnstein K, Cato L, et al. Role of androgen receptor variants in prostate cancer: report from the 2017 mission androgen receptor variants meeting. European Urology. 2018; 73: 715–723.

[36] Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocrine Reviews. 2004; 25: 276–308.

[37] Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Research. 2008; 68: 4447–4454.

[38] Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer. New England Journal of Medicine. 2019; 380: 1235–1246.

[39] Nuhn P, De Bono JS, Fizazi K, Freedland SJ, Grilli M, Kantoff PW, et al. Update on systemic prostate cancer therapies: management of metastatic castration-resistant prostate cancer in the era of precision oncology. European Urology. 2019; 75: 88–99.

[40] Mullane SA, Van Allen EM. Precision medicine for advanced prostate cancer. Current Opinion in Urology. 2016; 26: 231–239.

[41] Robinson D, Van Allen EM, Wu Y, Schultz N, Lonigro RJ, Mosquera J, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015; 162: 454.

[42] Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, et al. Placebo-controlled phase III trial of immunologic therapy with Sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. Journal of Clinical Oncology. 2006; 24: 3089–3094.

[43] Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJM, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. The Lancet Oncology. 2014; 15: 700–712.

[44] Fay EK, Graff JN. Immunotherapy in prostate cancer. Cancers. 2020; 12: 1752.

[45] Adam A, Ras R, Bhattu AS, Raman A, Perera M. “Researching the Research” in prostate cancer: a comparative bibliometric analysis of the top 100 cited articles in the field of prostate cancer. Current Urology. 2017; 11: 26–35.

[46] Patterson JT, Isaacson J, Kerwin L, Atassi G, Duggal R, Bresson D, et al. PSMA-targeted bispecific Fab conjugates that engage T cells. Bioorganic & Medicinal Chemistry Letters. 2017; 27: 5490–5495.

[47] Lai P, Liu YH, Xue JH, He PC, Qiu YQ. The 100 most-cited articles on aortic dissection. BMC Cardiovascular Disorders. 2017; 17: 30.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,200 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Directory of Open Access Journals (DOAJ) DOAJ is a unique and extensive index of diverse open access journals from around the world, driven by a growing community, committed to ensuring quality content is freely available online for everyone.

SCImago The SCImago Journal & Country Rank is a publicly available portal that includes the journals and country scientific indicators developed from the information contained in the Scopus® database (Elsevier B.V.)

Publication Forum - JUFO (Federation of Finnish Learned Societies) Publication Forum is a classification of publication channels created by the Finnish scientific community to support the quality assessment of academic research.

Scopus: CiteScore 0.7 (2022) Scopus is Elsevier's abstract and citation database launched in 2004. Scopus covers nearly 36,377 titles (22,794 active titles and 13,583 Inactive titles) from approximately 11,678 publishers, of which 34,346 are peer-reviewed journals in top-level subject fields: life sciences, social sciences, physical sciences and health sciences.

Norwegian Register for Scientific Journals, Series and Publishers Search for publication channels (journals, series and publishers) in the Norwegian Register for Scientific Journals, Series and Publishers to see if they are considered as scientific. (

Submission Turnaround Time